This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein (HSIC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Growth Investors Should Buy Staar Surgical (STAA) Now
by Zacks Equity Research
Staar Surgical (STAA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 42% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Staar Surgical (STAA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts See a 47% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 47.1% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bear of the Day: Align Technology (ALGN)
by Jeremy Mullin
Bears continue to show big smiles when looking at this medical name.
Wall Street Analysts Think Staar Surgical (STAA) Could Surge 76%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 75.9% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons Growth Investors Will Love Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Q1 Earnings Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 5.50% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q4 Earnings Top Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cloudflare (NET) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cloudflare's (NET) Q4 results likely to reflect benefits from its global expansion strategy, continuous addition of large amount customers and solid demand for security solutions amid the pandemic.
Twilio (TWLO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Twilio (TWLO) Q4 top line is likely to reflect benefits from newly acquired Zipwhip and Segment. Elevated spending on product and market expansions might have weighed on the bottom line.
Fortinet (FTNT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Fortinet's (FTNT) Q4 results are likely to reflect increased demand for IT security, stellar growth in Fortinet Security Fabric, cloud and SD-WAN offerings amid the pandemic-led remote working trend.
Staar Surgical (STAA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Conmed (CNMD) Tops Q4 Earnings Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 1.90% and 1.25%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Loses 14.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Staar Surgical (STAA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
New Strong Buy Stocks for January 13th
by Zacks Equity Research
STAA, OUT, XOM, STM, and ADI have been added to the Zacks Rank #1 (Strong Buy) List on January 13th.
Bear of the Day: Cardinal Health (CAH)
by David Bartosiak
Earnings are not as healthy as they could be.
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 31.25% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
by Zacks Equity Research
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
STAAR Surgical (STAA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
STAAR Surgical (STAA) has been struggling lately, but the selling pressure may be coming to an end soon.
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.